KOSDAQ Stock Exchange News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 4,
"returned": 4,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "fb8a4f05-fb5e-4f4f-8a6f-ad690fd8bcc2",
"title": "Global Pulmonary Drugs Market is Expected to Showcase a Significant Growth by 2030, Predicts DelveInsight | Key Companies - F. Hoffmann-La Roche, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Sa",
"description": "The global pulmonary drugs market is projected to experience a steady CAGR between 2024 and 2030. This growth is mainly attributed to the increasing...",
"keywords": "DelveInsight Business Research LLP, Pulmonary Drugs, Pulmonary Drugs Market, Pulmonary Drugs Trials, Pulmonary Drugs Companies, Pulmonary Drugs FDA",
"snippet": "New York, USA, April 25, 2024 (GLOBE NEWSWIRE) -- Global Pulmonary Drugs Market is Expected to Showcase a Significant Growth by 2030, Predicts DelveInsight | Ke...",
"url": "https://www.globenewswire.com/news-release/2024/04/25/2869948/0/en/Global-Pulmonary-Drugs-Market-is-Expected-to-Showcase-a-Significant-Growth-by-2030-Predicts-DelveInsight-Key-Companies-F-Hoffmann-La-Roche-AstraZeneca-Boehringer-Ingelheim-GlaxoSmi.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/dbcddd65-71dd-4559-8875-ae89ac4f96db",
"language": "en",
"published_at": "2024-04-25T17:00:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "064550.KQ",
"name": "Bioneer Corporation",
"exchange": null,
"exchange_long": null,
"country": "kr",
"type": "equity",
"industry": "Healthcare",
"match_score": 13.929144,
"sentiment_score": 0,
"highlights": [
{
"highlight": "EpiEndo Pharmaceuticals, 3SBio, OmniSpirant, Foresee Pharmaceuticals, Amgen, Organicell Regenerative Medicine, Arrowhead Pharmaceuticals, ProterixBio, RS BioTherapeutics, MitoRx, C4X Discovery, Respiratorius, ARK biosciences, Incannex, GNI Pharma, Celon pharma, Alveolus Bio, Kinaset therapeutics, Landos Biopharma, Parion Sciences, KeyMed Biosciences, <em>Bioneer</em>",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>corporation</em>, AlgiPharma, Palobiofarma, Dimerix Bioscience, Glenmark Pharmaceuticals, among others.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "b174929d-6ec3-475e-b8fc-75b1c4bd89a1",
"title": "JNK India IPO oversubscribed over 28 times, receives strong investor interest",
"description": "JNK India Ltd IPO oversubscribed 28 times, priced at ₹395-415, with proceeds for working capital and expansion.",
"keywords": "JNK India IPO, JNK India share price, QIB’s, overwhelming response, Non-institutions, Heating equipment IPO, IPO subscription news",
"snippet": "The initial public offering of heating equipment maker JNK India Ltd was subscribed over 28 times.\n\nThe issue, at a price band of ₹395-415, received bids for ...",
"url": "https://www.thehindubusinessline.com/markets/jnk-india-ipo-oversubscribed-over-28-times-receives-strong-investor-interest/article68106064.ece",
"image_url": "https://bl-i.thgim.com/public/incoming/lcez0r/article68106075.ece/alternates/LANDSCAPE_1200/JNK%20India.jpg",
"language": "en",
"published_at": "2024-04-25T13:01:38.000000Z",
"source": "thehindubusinessline.com",
"relevance_score": null,
"entities": [
{
"symbol": "126880.KQ",
"name": "JNK Heaters Co., Ltd.",
"exchange": null,
"exchange_long": null,
"country": "kr",
"type": "equity",
"industry": "Energy",
"match_score": 64.2484,
"sentiment_score": 0.5574,
"highlights": [
{
"highlight": "Promoters Goutam Rampelli, Dipak Kacharulal Bharuka, <em>JNK</em> <em>Heaters</em> <em>Co</em> <em>Ltd</em>, and Mascot Capital and Marketing Pvt Ltd, and shareholder Milind Joshi are offloading shares in the OFS.\n\nWhile the QIB was subscribed a whopping 75.72 times, the portion allocated to NIIs and retail investors received bids 23.19 times and 4 times, respectively.",
"sentiment": 0.5574,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "51c1609e-8ab3-4a02-b1e7-4141cbdc5ac4",
"title": "Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer By Investing.com",
"description": "Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer",
"keywords": "",
"snippet": "The only solution for intractable cancer caused by mutations in the p53 gene\n\nPlanning clinical trials targeting cancer patients with no available treatment due...",
"url": "https://www.investing.com/news/press-releases/hyundai-bioscience-announces-clinical-development-plan-for-niclosamidebased-metabolic-anticancer-drug-targeting-p53-mutation-cancer-93CH-3396828",
"image_url": "https://i-invdn-com.investing.com/news/World_News_10_800x533_L_1420026292.jpg",
"language": "en",
"published_at": "2024-04-25T09:36:06.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "187660.KQ",
"name": "ADM Korea",
"exchange": null,
"exchange_long": null,
"country": "kr",
"type": "equity",
"industry": "N/A",
"match_score": 44.683167,
"sentiment_score": -0.47825,
"highlights": [
{
"highlight": "Sang-ki Oh, CEO of Hyundai Bioscience, stated, \"Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells,\" and added, \"Through our subsidiary <em>ADM</em> <em>Korea</em>, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations",
"sentiment": -0.9565,
"highlighted_in": "main_text"
},
{
"highlight": "Jong-Eon Lim , CEO of <em>ADM</em> <em>Korea</em>, mentioned, \"We plan to submit IND for a clinical trial that is designed to compare the combination therapy group with niclosamide-based anticancer drug and existing anticancer drugs treatment against the single-agent therapy group,\" and added, \"With this clinical trial, we will advance into a biotech specialized in oral",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "2d138fd2-244a-44db-a25e-6124ea0192e9",
"title": "IPO screener: JNK India issue closes today",
"description": "JNK India Ltd's IPO closes today with 1.03x subscription, offering heating equipment for various industries.",
"keywords": "IPO screener, JNK India, NSE, BSE, SENSEX, NIFTY, share market",
"snippet": "The initial public offering of heating equipment maker JNK India Ltd will close today. The IPO was subscribed 1.03 times so far.\n\nThe issue, at a price band of ...",
"url": "https://www.thehindubusinessline.com/markets/ipo-screener-jnk-india-issue-closes-today/article68104619.ece",
"image_url": "https://bl-i.thgim.com/public/incoming/dvwtr5/article68027018.ece/alternates/LANDSCAPE_1200/IMG_TH17-BU-IPO_2_1_OICI1S7B.jpg",
"language": "en",
"published_at": "2024-04-25T03:26:04.000000Z",
"source": "thehindubusinessline.com",
"relevance_score": null,
"entities": [
{
"symbol": "126880.KQ",
"name": "JNK Heaters Co., Ltd.",
"exchange": null,
"exchange_long": null,
"country": "kr",
"type": "equity",
"industry": "Energy",
"match_score": 62.18208,
"sentiment_score": 0.296,
"highlights": [
{
"highlight": "Those offloading shares in the OFS are promoters Goutam Rampelli, Dipak Kacharulal Bharuka, <em>JNK</em> <em>Heaters</em> <em>Co</em> <em>Ltd</em>, and Mascot Capital and Marketing Pvt Ltd, and a shareholder Milind Joshi.",
"sentiment": 0.296,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "KOSDAQ",
"total_documents": 4,
"sentiment_avg": 0.09378749877214432
}
]
}
Other details
Country
- kr
- 1,462